Equities Analysts Offer Predictions for TARS FY2025 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities research analysts at Lifesci Capital raised their FY2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Wednesday, November 5th. Lifesci Capital analyst C. Jubinville now expects that the company will post earnings of ($1.46) per share for the year, up from their previous estimate of ($1.54). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at $0.06 EPS.

Several other analysts have also weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. The Goldman Sachs Group reissued a “neutral” rating and issued a $51.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Guggenheim lifted their target price on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, HC Wainwright upped their target price on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research note on Monday, October 20th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $69.83.

Tarsus Pharmaceuticals Trading Down 0.2%

Tarsus Pharmaceuticals stock opened at $68.09 on Friday. The business has a 50 day moving average price of $62.57 and a two-hundred day moving average price of $51.09. The company has a quick ratio of 5.21, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals has a 12 month low of $38.51 and a 12 month high of $76.81. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -33.71 and a beta of 0.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The business had revenue of $118.70 million during the quarter, compared to analysts’ expectations of $114.22 million.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. Amalgamated Bank lifted its position in Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock worth $65,000 after buying an additional 295 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of Tarsus Pharmaceuticals in the second quarter worth about $227,000. Strs Ohio bought a new position in shares of Tarsus Pharmaceuticals in the first quarter worth about $288,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Tarsus Pharmaceuticals during the first quarter worth approximately $26,199,000. Finally, Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals by 5.3% during the first quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company’s stock valued at $114,380,000 after purchasing an additional 111,433 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Insider Activity

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total transaction of $332,220.00. Following the sale, the chief executive officer directly owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. This represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William J. Phd Link sold 27,116 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the sale, the director directly owned 143,332 shares of the company’s stock, valued at approximately $8,169,924. The trade was a 15.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 39,116 shares of company stock worth $2,177,832. 8.97% of the stock is owned by insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.